Vincristine Sulfate Injection 2 mg in 2 mL (4)

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

vincristine sulfate, Quantity: 1 mg/mL

Disponível em:

Pfizer (Perth) Pty Ltd

Forma farmacêutica:

Injection, solution

Composição:

Excipient Ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide

Via de administração:

Intravenous

Unidades em pacote:

5 x 2 mL

Tipo de prescrição:

(S1) This Schedule is intentionally blank

Indicações terapêuticas:

VINCRISTINE is effective in Hodgkins disease and other lymphomas. In Hodgkins disease it is effective for the advanced stages (III and IV) when used in the MOPP regime (mechlorethamine, oncovin, prednisone, procarbazine). In non-Hodgkins lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin and prednisone. Vincristine is also effective in lymphocytic leukemia. Beneficial responses have been reported in patients with a variety of other neoplasms, particularly Wilms tumour, neuroblastoma, brain tumours, rhabdomyosarcoma and carcinomas of the breast, bladder, and the female and male reproductive systems.

Resumo do produto:

Visual Identification: Clear and colourless solution; Container Type: Vial; Container Material: PP; Container Life Time: 24 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status de autorização:

Listed (Export Only)

Data de autorização:

2019-10-18